MOESM2 of Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases

Additional file 2: Table S1. Clinical table with age, gender, treatment, response distribution, PFS, mutational status, all number of samples, IC50 of the cell systems and the applied methods.附加文件2：表S1。该临床数据表包含受试者年龄、性别、治疗方案、应答分布、无进展生存期（Progression-Free Survival，PFS）、突变状态、总样本量、细胞系统的半最大效应浓度（Half maximal inhibitory concentration，IC50）以及所采用的实验方法。